Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

about

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Item

http://www.wikidata.org/entity/Q36230572

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@ast

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@en

type

Item

label

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@ast

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@en

prefLabel

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@ast

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@en

P1476

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

@en

P2093

Carlo Alberto Maggi

http://www.w3.org/2001/XMLSchema#string

Cecilia Simonelli

http://www.w3.org/2001/XMLSchema#string

Cristina Goso

http://www.w3.org/2001/XMLSchema#string

Mario Bigioni

http://www.w3.org/2001/XMLSchema#string

Monica Binaschi

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

The epigenomics of cancer

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Tumour stem cells and drug resistance

Epigenetic stem cell signature in cancer

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

P304

173-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2011.192

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230850798

http://www.w3.org/2001/XMLSchema#string

P698

22977486

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

3440680

http://www.w3.org/2001/XMLSchema#string